LGND has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LGND has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-13), Ligand Pharmaceuticals's current share price is $87.28. Ligand Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $3.41. Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is 25.60.
The historical rank and industry rank for Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
During the past years, Ligand Pharmaceuticals's highest Cyclically Adjusted Price-to-FCF was 1014.60. The lowest was 13.58. And the median was 40.47.
LGND's Cyclically Adjusted Price-to-FCF is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Ligand Pharmaceuticals's adjusted free cash flow per share data for the three months ended in Mar. 2024 was $0.893. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $3.41 for the trailing ten years ended in Mar. 2024.
The historical data trend for Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ligand Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | 20.66 | 20.16 | 16.41 | 21.45 | 21.41 |
For the Biotechnology subindustry, Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is calculated as
Cyclically Adjusted Price-to-FCF | = | Share Price | / | Cyclically Adjusted FCF per Share |
= | 87.28 | / | 3.41 | |
= | 25.60 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ligand Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Ligand Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 0.893 | / | 129.4194 | * | 129.4194 | |
= | 0.893 |
Current CPI (Mar. 2024) = 129.4194.
Ligand Pharmaceuticals Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201406 | 0.182 | 100.560 | 0.234 |
201409 | 0.162 | 100.428 | 0.209 |
201412 | 0.369 | 99.070 | 0.482 |
201503 | 0.209 | 99.621 | 0.272 |
201506 | 0.262 | 100.684 | 0.337 |
201509 | 0.427 | 100.392 | 0.550 |
201512 | 0.548 | 99.792 | 0.711 |
201603 | 0.333 | 100.470 | 0.429 |
201606 | -0.398 | 101.688 | -0.507 |
201609 | 0.710 | 101.861 | 0.902 |
201612 | 1.230 | 101.863 | 1.563 |
201703 | 0.835 | 102.862 | 1.051 |
201706 | 0.447 | 103.349 | 0.560 |
201709 | 1.174 | 104.136 | 1.459 |
201712 | 1.297 | 104.011 | 1.614 |
201803 | 2.450 | 105.290 | 3.011 |
201806 | 3.014 | 106.317 | 3.669 |
201809 | 1.126 | 106.507 | 1.368 |
201812 | 1.418 | 105.998 | 1.731 |
201903 | 2.127 | 107.251 | 2.567 |
201906 | -3.122 | 108.070 | -3.739 |
201909 | -0.330 | 108.329 | -0.394 |
201912 | -0.408 | 108.420 | -0.487 |
202003 | 1.024 | 108.902 | 1.217 |
202006 | 1.461 | 108.767 | 1.738 |
202009 | 0.793 | 109.815 | 0.935 |
202012 | 0.029 | 109.897 | 0.034 |
202103 | 0.426 | 111.754 | 0.493 |
202106 | 1.106 | 114.631 | 1.249 |
202109 | 1.065 | 115.734 | 1.191 |
202112 | 1.461 | 117.630 | 1.607 |
202203 | 2.802 | 121.301 | 2.990 |
202206 | 0.310 | 125.017 | 0.321 |
202209 | 0.887 | 125.227 | 0.917 |
202212 | 3.096 | 125.222 | 3.200 |
202303 | 1.754 | 127.348 | 1.783 |
202306 | -0.016 | 128.729 | -0.016 |
202309 | 0.412 | 129.860 | 0.411 |
202312 | -2.415 | 129.419 | -2.415 |
202403 | 0.893 | 129.419 | 0.893 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thank you for viewing the detailed overview of Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Martine Zimmermann | director | C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD SUITE 110, SAN DIEGO CA 92121 |
Todd C Davis | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Andrew Reardon | officer: CHIEF LEGAL OFFICER & | C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121 |
Octavio Espinoza | officer: Chief Financial Officer | C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121 |
John W Kozarich | director | 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121 |
Stephen L Sabba | director | DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791 |
John L Higgins | officer: CEO & President | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Jason Haas | director | C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140 |
Matthew W Foehr | officer: EVP and COO | 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037 |
John L Lamattina | director | 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454 |
Jennifer R. Cochran | director | C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121 |
Charles S Berkman | officer: Asso. Gen. Counsel, Secretary | 11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037 |
Sunil Patel | director | 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037 |
Goldman Sachs Group Inc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
Goldman Sachs & Co. Llc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
From GuruFocus
By Value_Insider Value_Insider • 12-08-2022
By Business Wire Business Wire • 04-24-2023
By Business Wire • 07-27-2023
By Business Wire Business Wire • 12-13-2022
By Business Wire • 10-25-2023
By Business Wire • 07-25-2023
By PRNewswire PRNewswire • 02-16-2023
By Business Wire • 09-21-2023
By Business Wire Business Wire • 02-06-2023